Therapeutic Solutions International Inc (TSOI)

[centsability4me]

latest 10 Q out
https://ih.advfn.com/p.php?pid=nmona&article=78690892

NanoStilbene Clinical Study in Cancer
1)
Pharmacokinetics of blood serum concentration across a prescribed period of time. This involves the study of the bodily absorption, distribution, metabolism, and excretion of drugs and the characteristic interactions of a drug and the body in terms of its absorption, distribution, metabolism, and excretion. This has been completed as of this writing.



2)
A small pilot study is in the planning stages to be performed under the direction of Dr. Santosh Kesari at John Wayne Cancer Institute in Santa Monica CA. by conducting a clinical trial assessing the effects of pterostilbene in modulating immune response and inflammatory parameters in a group of advanced solid tumor cancer patients. This has been completed as of this writing.



3)
Publication by Dr. Kesari, Dr. Ichim and other members of our team. This is currently underway.

Additional StemVacs Platform Immunotherapeutics

NanoStilbene: Patented Augmenter of Cancer Immunotherapy



NanoStilbene , a nanoparticle formulation of pterostilbene, is covered for use in cancer immunotherapy under the Company’s issued U.S. Patent No.: 9,682,047 and is included as part of the Prostate and Breast Cancer Protocol with StemVacs